MAPT and Alzheimer disease: Thus, these figures fall within the reported detection range for being used in Tau concentration as an AD biomarker in serum because abnormal levels of Tau protein are reported as values higher than 450 pg/mL in CSF [32] or more than 30 pg/mL in serum [35].